NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Why did these occur on two different dates Senti?


1. In December 2022, CRISPR Therapeutics and Vertex Pharmaceuticals completed regulatory submissions for exa-cel with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in ….the U.K., respectively. https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-5


2. (February 6, 2023) Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics (NASDAQ: CRSP) have announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has validated the Marketing Authorisation Application (MAA) of exa-cel for the treatment of sickle cell disease (SCD) and transfusion dependent beta thalassaemia (TDT) in Great Britain.
Vertex-and-CRISPR-Therapeutics-Announce-MHRA-Marketing Authorisation Application Validation for CRISPR/Cas9 Gene-Edited
Published: February 6, 2023


https://www.technologynetworks.com/genomics/product-news/vertex-and-crispr-therapeutics-announce-mhra-marketing-authorisation-application-validation-for-369926[/url][tag]insert-text-here